spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Nanobiotix announces that Bpifrance has awarded the company an interest free loan

Nanobiotix

Bpifrance grants Nanobiotix a €2M interest-free loan to support final development stage of lead product, NBTXR3

Paris, France, and Cambridge, Massachusetts, USA, September 19, 2016 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of €2M for Innovation (prêt à taux zéro pour l’Innovation - PTZI).

The interest-free loan, repayable from September 2019, aims to support the development of Nanobiotix’s lead product, NBTXR3, which is currently under registration trial (Phase II/III) with Soft Tissue Sarcoma. Nanobiotix has recently filed for a CE Mark for the product.

A nanomedicine product in registration phase

NBTXR3 is a first-in-class radio-enhancer based on the NanoXray technology, designed for direct injection into cancerous tumors. The product is engineered to increase the dose and efficacy of radiotherapy without increasing toxicity or causing damage to surrounding healthy tissues.

NBTXR3 is currently in clinical development in six indications: Soft Tissue Sarcoma, Head and Neck cancers, Prostate, Liver cancers (primary and metastases) and rectal (via PharmaEngine, partner for the Asia Pacific area). Philippe Mauberna, CFO of Nanobiotix, commented: “Bpifrance has shown Nanobiotix a continual high level of support since our inception for which we are very pleased. This interest-free loan will contribute to financing the last steps of the NBTXR3 registration study in Soft Tissue Sarcoma. This is an exciting period for the Company.”

Bpifrance, a historic partner of the Company


Bpifrance (ex OSEO), has supported Nanobiotix’s dynamic development for over 12 years. This support has taken a number of forms such as repayable grants or inclusion in Strategic Industrial Innovation (ISI) programs, such as the “NICE project”, a collaborative project dedicated to liver cancers and managed by Bpifrance.

Eric Tossah, Bpifrance, commented: "The Bpifrance team is delighted to put this new loan together for Nanobiotix which demonstrates our deep support and confidence in this innovative French technology. Nanobiotix is rapidly growing with an international and renowned management team. They launched an affiliate in the Boston area two years ago, and have welcomed a number of North American life sciences specialist investors."
phone +33 (1) 40 26 04 70
web www.nanobiotix.com
email NGIN, 210 Broadway Cambridge, MA02139, US
 
Print this page
Send to a friend
   
spacer
News and Press Releases

PCI Pharma Services Announces Release of Joint White Paper with Domino on Ink Leachability in Pharmaceutical Serialization

Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the release of a published white paper detailing Domino’s study which analyzes potential leachability of ink from coding technologies used in pharmaceutical Serialization activities. The study was executed to ensure no migration into drug product contained within HDPE bottles with directly applied codes. Domino is an industry leader in coding and printing technologies operating in over 120 countries worldwide, and one of the key providers of coding technologies to PCI across its global supply network.
More info >>


White Papers

Tabletability, Compactability, and Compressibilty: What’s the Difference?

Natoli Engineering Company, Inc.

To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. That’s where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >>

Industry Events

14th World Advanced Therapies & Regenerative Medicine Congress 2018

16-18 May 2018, Business Design Centre, London, United Kingdom

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products).
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement